Unibep – Improved margins and order book growth

The financial results of 2Q'25 show the positive effects of the activities carried out to improve the profitability of contracts. The gross margin on sales in the construction segment reached 7.7% and the operating profitability reached 4.3%, levels not observed in Unibep S.A. for 5 years. In recent months, the company has been acquiring a larger number of orders, standing out positively from other construction companies. The Group's order book at the end of Q3'25 is likely to exceed PLN 4 billion and will be at a record high. Net debt in the last quarter, despite the intensification of works in the summer season, decreased, and thanks to the advances received for the implementation of contracts, it may fall by the end of this year. We are increasing the target price per share from PLN 14.3 to PLN 15.0 within 9 months. We recommend buying shares.

Good quality results in 2Q'25, but disturbed by high financial costs and CIT

We assess the financial results of the 2nd quarter of 2025 neutrally. A strong point was the high gross profitability on sales achieved on construction activities in Unibep S.A. – in general and energy construction. However, the positive assessment of the results was overshadowed by significant financial costs and a high income tax rate (39% CIT rate in 2Q'25). However, nearly half of the financial costs were accounting in nature and were not related to the outflow of cash from Unibep. In the coming quarters, we expect lower financial costs and a significantly lower income tax rate.

Positive prognosis for the coming quarters

The order book in 2Q'25 increased to PLN 3.5 billion, at the end of 3Q'25 we expect an increase to a record PLN 4 billion. We believe that a large number of orders acquired in the current environment of stable prices of construction materials and subcontracting costs will enable the company to achieve satisfactory margins in the next few quarters. Thanks to the anticipated payments of advances for the execution of contracts, net debt may continue to decrease in the coming months. In the coming months, we also expect higher sales of apartments by Unidevelopment, thanks to the introduction of investments in Warsaw, in Praga Południe, at Omurewska Street in September.

Risk factors

In the medium term, slightly negative elements for the company are: the ongoing dispute with the Customs and Tax Office in Poznań and the lack of valorization of the contract for the construction of the provincial road No. 513. In both cases, however, we see a chance for favorable outcomes for Unibep.

We estimated the value of Unibep shares on the basis of the DCF valuation at PLN 12.8 and the comparative valuation at PLN 14.9. We assigned equal weights to both methods -50% each. We have set the target price for the 9-month horizon at PLN 15.0, which gives a 50% growth potential.

PLN m	2022	2023	2024*	2025F	2026F	2027F
Revenues	2 258.3	2 429.8	2 606.9	2 533.2	2 729.0	2 935.0
EBITDA adj.	89.3	-109.4	98.6	118.0	124.1	123.2
EBIT adj.	63.8	-137.8	68.3	86.7	91.9	89.7
Net profit adj.	7.4	-165.9	-0.7	30.6	50.1	53.3
EPS	0.21	-4.73	-0.02	0.87	1.43	1.52
DPS	0.50	0.22	0.00	0.20	0.25	0.30
P/E (x)	47.1	-	-	11.5	7.0	6.6
EV/EBITDA (x)	5.1	-	4.9	4.4	4.1	4.0

Source: Unibep. F - Noble Securities' forecasts

2024* results without taking into account +PLN 100.3 million EBIT and +PLN 45.6 million net profit attributable to shareholders of the parent company on land revaluation

The preparation of report was finalized on 26/09/2025 at 8:55 A.m.. The first publication took place on 26/09/2025 at 9:15 a.m.



BUY

Update report

Current price	PLN 10.0
Valuation	PLN 15.0
Upside/downside	50%
Market cap.	PLN 351 m
Free float	47%
Avg. Vol. 6M	16 900



Source: Bloomberg. Noble Securities

COMPANY PROFILE

Unibep is one of the largest construction groups in Poland. operating in the construction. infrastructure. energy and industrial. modular and development industries.

SHAREHOLDERS	
Zofia Mikołuszko	24.5%
Beata Maria Skowrońska	14.3%
Allianz OFE	10.0%
Bankowy OFE	9.2%
Joanna Małgorzata Stajkowska- Bastoui	7.1%
Own shares	6.4%
Others	28.5%
Source: Unibep S.A.	

Dariusz Nawrot

Senior Equity Analyst

dariusz.nawrot@noblesecurities.pl +48 783 931 515



VALUATION

We have valued Unibep's shares using two methods: DCF with a weight of 50% and a comparative analysis with a weight of 50% (unchanged from the valuation of May 6, 2025).

Over a 9-month horizon, we set the target price of Unibep shares at PLN 15.0 (previously PLN -14.3). We did not take into account one-off events in the valuation.

In table below we present valuation summary:

Valuation summary	Weight (x)	Per share (PLN)	Previously	Change
DCF valuation	50%	12.8	12.0	6%
Peers valuation	50%	14.9	14.5	3%
Average weighted valuation		13.8	13.2	5%
Target price (9M)		15.0	14.3	5%
Currnet price		10.0	10.6	-6%
Upside		50%	35%	

Source: Noble Securities

DCF VALUATION

Assumptions:

- Financial forecasts for 2025 2034 (unchanged).
- Cash flow discounted as at 25 September 2025 (previously as 6 May 2025).
- Net debt as at 31.12.2024 adjusted for dividend for 2024 PLN 110 million (previously PLN 103 million).
- Long-term growth rate after the forecast period equal to 1% (unchanged).
- Risk-free rate at 5.5% (previously 5.7%), risk premium 5.5% (unchanged).
- Beta at 1.0 (unchanged).
- Weighted average cost of capital at 9.9% (previously 10.1%).

DCF (PLN m)	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Revenues	2 514	2 734	2 921	3 067	3 220	3 381	3 550	3 728	3 914	4 110
NOPAT	65	72	71	74	77	81	85	89	94	99
Depreciation and amortization	31	32	34	34	35	36	36	37	38	38
Change in WC	-76	-14	-4	-13	-14	-22	-15	-28	-29	-31
CAPEX	-17	-21	-25	-32	-35	-36	-36	-37	-38	-38
FCFF	3	69	75	63	63	59	71	62	65	68
WACC	9,9%	9,9%	9,9%	9,9%	9,9%	9,9%	9,9%	9,9%	9,9%	9,9%
Discount factor	0,98	0,89	0,81	0,73	0,67	0,61	0,55	0,50	0,46	0,42
DFCFF	3	61	61	46	42	36	39	31	30	28

Sum of DFCFF to 2034	377
Growth rate (g)	1%
Residual value 2034	769
Discounted Residual value	320
Enterprise Value (EV)	697
Net debt at 31/12/2024	110
Minorities	139
Equity Value	448
Shares (m.)	35.1
Equity Value per share (PLN)	12.8

Sensitivity analysis										
Growth rate (g)										
	-1%	0%	1%	2%	3%					
WACC - 1.0%	12.9	13.9	15.3	17.0	19.4					
WACC - 0.5%	11.9	12.8	14.0	15.4	17.4					
WACC	11.0	11.8	12.8	14.0	15.6					
WACC + 0.5%	10.1	10.8	11.7	12.8	14.2					
WACC + 1.0%	9.4	10.0	10.8	11.7	12.9					



Below we present Cost of Equity and WACC calculation:

WACC	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Risk free rate	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%
Market risk premium	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%	5.5%
Beta	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Cost of equity	10.9%	10.9%	10.9%	10.9%	10.9%	10.9%	10.9%	10.9%	10.9%	10.9%
Effective tax rate	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%
Cost of debt	7.5%	7.5%	7.5%	7.5%	7.5%	7.5%	7.5%	7.5%	7.5%	7.5%
Cost of debt after tax bracket	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%
Net debt/EV	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%
WACC	9.9%	9.9%	9.9%	9.9%	9.9%	9.9%	9.9%	9.9%	9.9%	9.9%

Source: Noble Securities

PEERS VALUATION

We based the comparative analysis on the shares of 10 domestic construction companies. Their profiles are diverse, but the common feature is that they operate mainly in Poland and often face similar problems regarding the prices and availability of building materials and subcontractors.

In the table, we have included the forecasted P/E and EV/EBITDA ratios for 2025 - 2027 (previously 2024 - 2026). We assigned equal weights to all indicators: 16.7%.

On the basis of a comparative valuation, we received a valuation of 1 share at PLN 14.9 (previously – PLN 14.5). A slightly higher valuation than on 6 May this year results from an increase in the share prices of other construction companies.

A summary of the comparative valuation is presented below:

Commonative valuation	Market cap		P/E (x)		EV/EBITDA (x)			
Comparative valuation	(mln PLN)	2025F	2026F	2027F	2025F	2026F	2027F	
Budimex	13 342	19.9	17,4	16,9	11,2	10,0	9,7	
Elektrotim	510	14.0	11,8	10,9	9,0	7,6	7,2	
Erbud	390	-	13,6	10,6	5,8	4,0	3,8	
Mirbud	1 512	13.4	12,0	10,4	7,4	6,9	6,4	
Mostostal Zabrze	467	9.8	9,1	9,0	4,0	4,0	4,1	
Onde	509	24.5	16,3	14,1	12,7	10,6	9,3	
Pekabex	382	15.9	8,7	7,6	6,8	5,0	4,3	
Polimex	1 736	12.9	14,5	12,3	5,0	6,0	5,6	
Torpol	1 111	15.3	15,0	14,5	7,1	7,1	7,2	
ZUE	264	23.0	32,2	14,3	6,3	8,0	6,3	
Median		15.3	14,0	11,6	6,9	7,0	6,4	
Unibep	351	11.5	7,0	6,6	4,4	4,1	4,0	
Premium/discount to Median		-25%	-50%	-43%	-37%	-42%	-37%	
Implied fair value Unibep		13.32	20,08	17,67	12,49	13,91	12,17	
Indicator weight		17%	17%	17%	17%	17%	17%	
The weighted average value of 1 Unibep share				14.9				

Source: Noble Securities



Financial results and forecasts

Profil and loss account	2022	2023	2024	2025F	2026F	2027F
Net revenues	2 258.3	2 429.8	2 606.9	2 533.2	2 729.0	2 935.0
Gross profit from sales	148.3	-37.8	176.6	208.7	235.4	241.7
Cost of sales	-20.6	-15.5	-7.7	-14.0	-15.5	-17.0
SG&A costs	-58.3	-71.3	-101.2	-113.0	-125.0	-133.0
Other operating revenues and expenses	-5.6	-13.2	100.9	5.0	-3.0	-2.0
EBIT reported	63.8	-137.8	168.6	86.7	91.9	89.7
EBIT excludnig one off	63.8	-137.8	68.3	86.7	91.9	89.7
Financial income and costs	-21.9	-39.5	-41.9	-36.1	-26.9	-22.2
Profit before tax	41.9	-177.3	134.8	50.6	64.9	67.5
Income tax	-10.0	20.8	-27.1	-13.7	-14.3	-14.2
Net profit of the parent company's shareholders	31.9	-156.5	107.7	36.8	50.6	53.3
Net profit of the parent company's shareholders exc. one off	7.4	-165.9	-0.7	30.6	50.1	53.3
Deprecation and amortization	25.6	28.4	30.2	31.3	32.2	33.5
EBITDA	89.3	-109.4	98.6	118.0	124.1	123.2

Source: Unibep (2022-2024). Noble Securities (2025F-2027F)

Balance Sheet	2022	2023	2024	2025F	2026F	2027F
Assets	1 813.2	1 807.3	1 975.5	1 958.6	2 020.1	2 091.8
Non-current Assets	401.1	350.8	474.1	468.0	482.0	502.0
Tangible assets	152.3	146.8	152.6	158.0	166.0	172.0
Intangible assets	23.9	24.6	22.3	23.0	24.0	25.0
Other non-current assets	224.9	179.4	299.2	287.0	292.0	305.0
Current Assets	1 412.1	1 456.5	1 501.4	1 490.6	1 538.1	1 589.8
Inventories	543.5	457.9	406.5	433.4	463.5	494.0
Trade receivables	384.5	378.9	402.9	439.9	459.2	480.1
Cash and cash equivalents	137.9	311.1	262.5	207.3	200.4	195.7
Other current assets	346.1	308.6	429.5	410.0	415.0	420.0

Liabilities	1 813.2	1 807.3	1 975.5	1 958.6	2 020.1	2 091.8
Equity	302.1	136.9	180.2	204.3	246.2	289.7
Non-current liabilities	298.0	410.3	419.0	412.3	404.3	396.3
Loans. borrowings and other financial liabilities	169.7	254.9	251.3	240.3	229.3	218.3
Other	128.2	155.4	167.7	172.0	175.0	178.0
Current liabilities	1 131.3	1 183.9	1 237.2	1 203.0	1 230.5	1 266.7
Loans. borrowings and other financial liabilities	71.1	72.7	143.9	129.9	127.9	121.9
Accounts payable	415.3	416.7	410.2	395.5	424.2	458.2
Other	644.9	694.5	683.1	677.6	678.4	686.7

 $Source:\ Unibep\ (2022-2024).\ Noble\ Securities\ (2025F-2027F)$



Cash flow statement	2022	2023	2024F	2025F	2026F	2027F
Profit before tax	41.9	-177.3	134.8	50.6	64.9	67.5
Depreciation and amortization	25.6	28.4	30.2	31.3	32.2	33.5
Change in working capital	-137.1	92.6	20.9	-78.6	-20.7	-17.4
Income tax paid	0.0	20.8	-45.1	-13.7	-14.3	-14.2
Others	65.4	192.6	-223.6	0.0	0.0	0.0
CF from operating activities	-4.2	157.1	-82.7	-10.5	62.2	69.4
CAPEX	-70.7	-6.6	-9.8	-17.0	-21.0	-25.0
Divestments and other	13.5	10.4	31.0	40.0	0.0	0.0
CF from investment activities	-57.3	3.8	21.2	23.0	-21.0	-25.0
Increase of share capital	0.0	0.0	0.0	0.0	0.0	0.0
Change of financial liabilities	7.4	84.6	63.5	-25.0	-13.0	-17.0
Other	-16.3	-7.1	0.0	-6.6	-8.2	-9.8
Dividends and other proceeds to shareholders	-63.1	-65.2	-50.5	-36.1	-26.9	-22.2
CF from financial activities	-72.1	12.3	13.0	-67.7	-48.1	-49.1
CF	-133.5	173.3	-48.6	-55.2	-7.0	-4.7
Cash at the beginning of the period	271.5	137.9	311.1	262.5	207.3	200.4
Cash at the end of the period Source: Unibep (2022-2024). Noble Securities (2025F-2027F)	137.9	311.1	262.5	207.3	200.4	195.7
Source. Onloop (2022-2024). Noble Securities (20231-20271)						
Selected indicators	2022	2023	2024F	2025F	2026F	2027F
EPS. Adj+ (PLN)	0.21	-4.73	-0.02	0.87	1.43	1.52
Revenue (mln PLN)	2258.3	2429.8	2606.9	2533.2	2729.0	2935.0
Gross Margin %	6.6%	-1.6%	6.8%	8.2%	8.6%	8.2%
EBIT (mln PLN)	63.8	-137.8	68.3	86.7	91.9	89.7
EBITDA (mln PLN)	89.3	-109.4	98.6	118.0	124.1	123.2
Pre-Tax Profit	41.9	-177.3	134.8	50.6	64.9	67.5
Net Income Adj+ (mln PLN)	7.4	-165.9	-0.7	30.6	50.1	53.3
Net debt (mln PLN)	102.8	16.6	132.7	162.9	156.9	144.5
BPS (PLN)	8.62	3.90	5.14	5.83	7.02	8.26
DPS (PLN)	0.50	0.22	0.00	0.20	0.25	0.30
Return on Equity (ROE)	2%	-76%	0%	16%	22%	20%
Return on Assets (ROA)	0%	-9%	0%	2%	3%	3%
Depreciation (mln PLN)	0.0	0.0	0.0	0.0	0.0	0.0
Amortization (mln PLN)	25.6	28.4	30.2	31.3	32.2	33.5
Free Cash Flow (mln PLN)	-75.0	150.5	-92.6	-27.5	41.2	44.4
CAPEX (mln PLN)	70.7	6.6	9.8	17.0	21.0	25.0

Source: Calculated by Noble Securities



LEGAL DISCLAIMER

FUNDAMENTAL RULES FOR ISSUING ANALYTICAL REPORT

This analytical report. hereinafter referred to as the "Report". was prepared by Noble Securities S.A. ("NS") based in Warsaw.

The basis for the preparation of the Report were publicly available information known to the Analyst as at the date of preparing the Report. in particular information provided by the Issuer in current and periodic reports prepared as part of its disclosure obligations.

The Report only expresses the analyst's knowledge and views as at the date of its preparation.

The forecasts and evaluation elements presented in the Report are based solely on the analysis performed by the Analyst. without arrangements with the Issuer or with other entities. and are based on a number of assumptions that may turn out to be irrelevant in the future.

NS or the Analyst do not give any assurance that the forecasts will work.

The report issued by NS is valid for a period of 24 months. unless it is previously updated. The frequency of updates results from the date of publication by the Issuer of financial results for a given reporting period, the market situation or subjective assessment of the Analyst.

STRONG AND WEAKNESSES OF VALUATION METHODS APPLIED BY NS IN THE REPORT

The DCF (eng. discounted cash flow) method - is considered the methodologically most appropriate valuation technique and consists in discounting financial flows generated by the rated entity. Strengths of this method include taking into account all cash flows that flow in and out of the company and the cost of money over time. The disadvantages of the DCF valuation method are: a large number of assumptions and parameters that need to be estimated and the sensitivity of valuation to changes in these factors. A variation of this method is the discounted dividend method.

Peers valuation - is based on a comparison of valuation multipliers of companies in the industry in which the rated entity operates. This method very well reflects the current state of the market requires fewer assumptions and is simpler to apply (relatively high availability of indicators for compared entities). Its disadvantages include high volatility related to price fluctuations and stock exchange indices (in the case of comparison to listed companies). subjectivism in the selection of a group of comparable companies and simplification of the company image leading to the omission of some important parameters (eg growth rate. corporate governance. non-operational assets. differences in accounting standards).

INTERESTS OR CONFLICTS OF INTERESTS THAT MAY AFFECT THE REPORTING OBJECTIVITY OF THE REPORT

The report was prepared by NS for consideration. on behalf of the Warsaw Stock Exchange S.A.

The Analyst is not a party to any contract concluded with the Issuer and does not receive remuneration from the Issuer. The Analyst's remuneration for preparing the Report due from NS is not directly related to transactions in brokerage services provided by NS or other types of transactions carried out by NS or any other legal entity that is part of the group to which NS belongs or with transaction fees that they receive NS or these people. It can not be ruled out that the remuneration that may be due in future to a NS Analyst by another title may be indirectly dependent on NS financial results. including those obtained as part of investment banking transactions related to the Issuer's financial instruments. The Analyst is not a party to any contract concluded with the Issuer and does not receive remuneration from the Issuer. The Analyst's remuneration for preparing the Report due from NS is not directly related to transactions in brokerage services provided by NS or other types of transactions carried out by NS or any other legal entity that is part of the group to which NS belongs or with transaction fees that they receive NS or these people. It can not be ruled out that the remuneration that may be due in future to a NS Analyst by another title may be indirectly dependent on NS financial results. including those obtained as part of investment banking transactions related to the Issuer's financial instruments.

It is possible that NS has or will have the intention to submit an offer to provide services to the Issuer.

ORGANIZATIONAL AND ADMINISTRATIVE SOLUTIONS AND INFORMATION BARRIERS ESTABLISHED TO PREVENT CONFLICT OF INTERESTS AND TO AVOID THEMSELVES

Detailed rules of conduct in the event of conflicts of interest are set out in the "Regulations of Conflicts of Interest Management at Noble Securities SA" available at the website www.noblesecurities.pl in the tab: "About us" / "Regulations" / "Information policy".

The internal structure of NS ensures organizational separation of analysts from individuals (teams) performing activities that involve the risk of a conflict of interest and prevents conflicts of interest, and in the event of such conflict enables protection of the Client's interests against the harmful effects of this conflict. In particular, Analysts do not have access to information about transactions concluded on the NS's own account and to Client orders. NS ensures that there is no possibility for third parties to exert any adverse influence on the performance of the work by Analysts. NS ensures that there are no links between the amount of remuneration of employees of one organizational unit and the amount of remuneration of employees of another organizational unit. or the amount of income earned by that other organizational unit, if these units perform activities that involve the risk of a conflict of interests

NS has implemented internal regulations regarding the flow of confidential and professional information. which is aimed at securing confidential information or professional secrecy and preventing its unjustified flow or misuse. NS limits to a minimum the circle of people who have access to confidential information or professional secrecy. In order to control access to relevant non-public information. within NS there are internal limitations and barriers in the transfer of information. so-called *Chinese walls*. i.e. rules. procedures and physical solutions to prevent the flow and use of confidential information and constitute professional secrecy. NS uses restrictions in physical access (separate rooms. lockable filling cabinets) and in access to information systems.

NS has implemented regulations in the scope of performing activities consisting in preparing investment analyzes. financial analyzes and other general recommendations regarding transactions in financial instruments, as well as the internal procedure regulating the subject scope. NS discloses in the content of Reports prepared by itself all connections and circumstances that could affect the objectivity of the Reports being prepared. It is forbidden to accept material or non-material benefits by NS or the Analyst from entities having a significant interest in the content of the Report. suggesting to the Issuer by NS or Analyst content favorable to that Issuer. It is forbidden to make available to the Issuer or other persons than Analysts. the Report. containing the content of the recommendation or the target price. before commencing its distribution for purposes other than verification of the NS's compliance with its legal obligations.

NS has implemented internal regulations regarding the rules of concluding personal transactions by involved persons. including prohibits the use of information obtained in connection with business activities for personal transactions. In addition. Analysts may not enter into personal transactions regarding the Issuer's financial instruments or related financial instruments prior to the dissemination of the Report. as well as personal transactions that conflict with the content of the Report and when NS starts or works on issuing Issuer's financial instruments since the Insurer's information in in this respect until the prospectus is published - in the case of a public offer or for launching an offer.


OTHER INFORMATION AND RESERVATIONS

NS ensures that the Report has been prepared with due diligence and integrity based on generally available facts and information recognized by the Analyst as reliable. reliable and objective. however NS nor the Analyst does not guarantee that they are fully accurate and complete. If the Report indicates the addresses of the websites used in the preparation of the Report. neither the Analyst nor NS takes responsibility for the content of these websites.

Investing can involve high investment risk. The analytical report cannot be treated as an assurance or guarantee of avoiding losses. or achieving potential or expected results. in particular profits or other benefits from transactions carried out on its basis. or in connection with refraining from such transactions. A general description of financial instruments and the risk related to investing in individual financial instruments is presented at www.noblesecurities.pl in the tab Brokerage House / Brokerage Account/ Documents. NS points out that although the above information has been prepared with due diligence. in particular in a reliable manner and in accordance with NS's best knowledge. It may not be exhaustive and may exist or be updated in the specific situation in which an investor is or will be located other risk factors than those indicated in the above information by NS. The investor should bear in mind that investments in individual financial instruments may result in the loss of some or all of the funds invested, and even involve the additional costs.

Investors using the Report may not resign from independent assessment and take into account other circumstances than indicated by the Analyst or by NS.

The Report has been prepared in accordance with legal requirements ensuring independence. in particular from the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards concerning technical means for the purpose of presenting investment recommendations or other information recommending or suggesting an investment strategy and disclosing particular interests or indications of conflicts of interest. The report is an investment study referred to in art. 36 par. 1 Commission Delegated Regulation (EU) 2017/565





of 25 April 2016 supplementing Directive 2014/65 / EU of the European Parliament and of the Council with regard to organizational requirements and operating conditions for investment firms and concepts defined for the purposes of this directive.

The Report or any of its entries do not state:

- offer within the meaning of art. 66 of the Act of 23 April 1964 the Civil Code.
- grounds for concluding a contract or creating a liability.
- public offering of financial instruments within the meaning of art. 3 of the Act of July 29. 2005 on Public Offering. Conditions Governing the Introduction of Financial Instruments to Organized Trading. and Public Companies.
- $\bullet\;$ invitations to subscribe for or purchase securities of the Issuer.
- investment advisory services or portfolio management services referred to in the Act of 29 July 2005 on Trading in Financial Instruments.
- investment. legal. accounting or other types of advice.

The Report

- is published on the NS website: https://noblesecurities.pl/dom-maklerski/analizy2/program-wsparcia-pokrycia-analitycznego-gpw/1796-bioton-s-a.
- is intended for distribution only on the territory of the Republic of Poland. and is not intended for distribution or transmission. directly or indirectly in the United States of America. Canada. Japan or Australia. or any other jurisdiction. where such distribution would violate relevant provisions of the given jurisdiction or required registration in that jurisdiction.
- does not contain all information about the Issuer and does not allow full assessment of the Issuer. in particular as regards the Issuer's financial situation. because only certain data regarding the Issuer were selected for the Report.
- is for information purposes only. so it is not possible to comprehensively evaluate the Issuer based on the Report.

FINAL REMARKS

Analyst preparing the Report: Dariusz Nawrot

Date and time of completion of the Report: 26/09/2025 at 8:55 a.m. Date and time of the first dissemination of the Report: 26/09/2025 at 9:15 a.m.

The proprietary copyrights to the Report are hold by the Stock Exchange in Warsaw S.A. Dissemination or reproduction of the Report (in whole or in any part) without the written consent of the Warsaw Stock Exchange S.A. is forbidden.

NS is subject to the supervision of the Polish Financial Supervision Authority.

Recently issued recommendations/updates regarding Unibep S. A.								
Recommendation/update n/a	n/d	n/d	n/d	n/d				
Release date	15/09/2023	9/05/2024	27/06/2024	20/12/2024	6/05/2025			
Price at the date of the report	10.4	9.5	9.4	6.98	10.6			
Target price	12.0	12.0	12.8	11.7	14.3			
WIG at the valuation date	67 368.11	87 427.54	88 135.13	79 577.32	99 195.99			



All recommendations distributed by NS in last 12 months:

an recommendations d	istributed by	NS III Iast 1.			Difference to	Data of publication	Validity data	
Company	Direction	Target Price (4)	Price at publication	Current price	Difference to price target	Date of publication (1)	Validity date (2)	Prepared by (3)
Huuuge	Accumulate	27,30	23,10	23,10	18%	24.09.2025	9M	Mateusz Chrzanowski
Budimex	Accumulate	560,00	518,20	522,60	7%	18.09.2025	9M	Dariusz Nawrot
Huuuge	Buy	27,80	22,00			18.09.2025	9M	Mateusz Chrzanowski
Creepy Jar	Hold	495,00	455,00	447,00	11%	16.09.2025	9M	Mateusz Chrzanowski
Eurocash	Accumulate	9,50	8,10	8,14	17%	15.09.2025	9M	Dariusz Dadej
Creotech Instruments	Accumulate	371,00	324,00	339,00	9%	15.09.2025	9M	Krzysztof Radojewski
Tauron PE	Sell	7,17	9,35	8,47	-15%	8.09.2025	9M	Michał Sztabler
MO-BRUK	Accumulate	338,00	295,00	279,50	21%	8.09.2025	9M	Dariusz Dadej
Bogdanka	Reduce	19,22	23,20	23,85	-19%	19.08.2025	9M	Michał Sztabler
Forte	Buy	33,90	27,30	27,00	26%	18.08.2025	9M	Dariusz Dadej
Apator	Accumulate	23,20	20,40	24,20	-4%	22.07.2025	9M	Michał Sztabler
Selvita	Buy	51,10	31,90	37,80	35%	18.07.2025	9M	Krzysztof Radojewski
Auto Partner	Buy	31,30	20,40	19,22	63%	3.07.2025	9M	Mateusz Chrzanowski
InterCars	Buy	774,10	568,00	559,00	38%	30.06.2025	9M	Mateusz Chrzanowski
Ailleron	Buy	24,10	19,70	18,08	33%	25.06.2025	9M	Dariusz Dadej
Captor Therapeutics	Buy	86,00	32,50	36,10	138%	24.06.2025	9M	Krzysztof Radojewski
Celon Pharma	Buy	33,70	21,80	21,80	55%	24.06.2025	9M	Krzysztof Radojewski
Molecure	Buy	11,90	5,70	7,47	59%	24.06.2025	9M	Krzysztof Radojewski
Ryvu Therapeutics	Buy	59,70	30,10	27,30	119%	24.06.2025	9M	Krzysztof Radojewski
Pepco Group	Accumulate	21,90	19,36	22,37	-2%	13.06.2025	9M	Dariusz Dadej
MO-BRUK	Accumulate	321,00	270,00			30.05.2025	9M	Dariusz Dadej
Photon Energy	na	3,70	3,50	2,91	27%	21.05.2025	9M	Michał Sztabler
Noctiluca	na	184,00	98,00	107,00	72%	15.05.2025	9M	Krzysztof Radojewski
Mabion	na	15,00	10,30	8,95	68%	15.05.2025	9M	Krzysztof Radojewski
Sonel		15,14	16,50	17,00	-11%	8.05.2025	9M	Michał Sztabler
	na							
Unibep	na	14,30	10,60	9,94	44%	6.05.2025	9M	Dariusz Nawrot
Budimex	Sell	515,00	640,00	522,60	-1%	29.04.2025	9M	Dariusz Nawrot
Answear.com	Accumulate	31,30	27,85	31,10	1%	22.04.2025	9M	Dariusz Dadej
TOYA	na	12,40	6,37	9,37	32%	17.04.2025	9M	Dariusz Nawrot
MCI Capital	na	42,20	23,90	29,30	44%	11.04.2025	9M	Krzysztof Radojewski
Budimex	Hold	510,00	529,00			7.04.2025	9M	Dariusz Nawrot
Aplisens	na	24,30	19,60	18,40	32%	2.04.2025	9M	Michał Sztabler
Ryvu Therapeutics	Buy	59,80	19,30			24.03.2025	9M	Krzysztof Radojewski
Dino Polska	Sell	35,84	48,82	45,37	-21%	19.03.2025	9M	Dariusz Dadej
Eurocash	Accumulate	9,90	9,32	15,57	2270	19.03.2025	9M	Dariusz Dadej
Budimex	Sell	510,00	632,00			13.03.2025	9M	Dariusz Nawrot
				4.55	40/			
Bioton	na	4,52	3,50	4,55	-1%	5.03.2025	9M	Krzysztof Radojewski
LPP	Buy	23 300,00	18 140,00	17955,00	30%	3.03.2025	9M	Dariusz Dadej
Huuuge	Buy	25,40	17,32			3.03.2025	9M	Mateusz Chrzanowski
Celon Pharma	Buy	37,50	23,20			21.02.2025	9M	Krzysztof Radojewski
Budimex	Reduce	510,00	557,00			14.02.2025	9M	Dariusz Nawrot
Torpol	Hold	39,40	39,70	48,30	-18%	12.02.2025	9M	Dariusz Nawrot
XTB	Buy	81,30	64,90	72,38	12%	11.02.2025	9M	Mateusz Chrzanowski
Forte	Accumulate	33,80	31,40			6.02.2025	9M	Dariusz Dadej
Photon Energy	na	5,36	4,40			3.02.2025	9M	Michał Sztabler
Answear.com	Hold	26,80	28,15			13.01.2025	9M	Dariusz Dadej
Unibep	na	11,70	6,98			20.12.2024	9M	Dariusz Nawrot
11bit studios		242,90	162,00	179,20	36%	19.12.2024	9M	Mateusz Chrzanowski
Ailleron	Buy Accumulate	242,90		113,20	30/0	16.12.2024	9M	Dariusz Dadej
			20,10					
Budimex	Buy	550,00	460,00			12.12.2024	9M	Dariusz Nawrot
Sonel	na -	16,61	15,40			12.12.2024	9M	Michał Sztabler
CD Projekt	Buy	222,90	169,20	255,00	-13%	2.12.2024	9M	Mateusz Chrzanowski
Bogdanka	Hold	22,34	23,00	23,85	-6%	2.12.2024	9M	Michał Sztabler
Wielton	Hold	5,31	5,50	7,36	-28%	2.12.2024	9M	Michał Sztabler
ХТВ	Buy	88,60	70,70			29.11.2024	9M	Mateusz Chrzanowski
Toya	na	12,40	7,50			29.11.2024	9M	Dariusz Nawrot
Molecure	Buy	17,60	10,30			29.11.2024	9M	Krzysztof Radojewski
Selvita	Buy	70,60	53,50			27.11.2024	9M	Krzysztof Radojewski
Tauron PE	Accumulate	3,94	3,60			26.11.2024	9M	Michał Sztabler
MO-BRUK	Accumulate	394,70	332,00			22.11.2024	9M	Dariusz Dadej
Pepco Group	Buy	20,68	15,77			20.11.2024	9M	Dariusz Dadej
Torpol	Buy	36,00	29,90			15.11.2024	9M	Dariusz Nawrot
11 bit studios	Buy	423,00	269,00			14.11.2024	9M	Mateusz Chrzanowski
Ryvu Therapeutics	Buy	74,40	48,60			14.11.2024	9M	Krzysztof Radojewski
Budimex	Accumulate	540,00	503,00			6.11.2024	9M	Dariusz Nawrot
Amica	Buy	82,30	58,00	58,40	41%	4.11.2024	9M	Mateusz Chrzanowski
PGE	Reduce	6,15	6,79	10,73	-43%	18.10.2024	9M	Michał Sztabler
		36,50	32,40	20,73	.570	14.10.2024	9M	Dariusz Nawrot
			32,4U			14.10.2024	JIVI	Dallusz NaWIOL
Torpol	Accumulate					0.10.3034	0.4	Vancout of Dealeter ald
Captor Therapeutics	Buy	127,90	73,00			8.10.2024	9M	Krzysztof Radojewski
						8.10.2024 30.09.2024 26.09.2024	9M 9M 9M	Krzysztof Radojewski Krzysztof Radojewski Mateusz Chrzanowski

⁽¹⁾ Date of publication is simultaneously date of first publication, (2) recommendation is valid for a period of 9 months, unless it is previously updated,

⁽³⁾ Job position: Krzysztof Radojewski – Deputy Head of Research and Advisory Department, Michał Sztabler – Equity Analyst, Dariusz Dadej - Equity Analyst, Mateusz Chrzanowski - Equity Analyst, Dariusz Nawrot - Senior **Equity Analyst**



MARKET RESEARCH DEPARTMENT

Sobiesław Kozłowski. MPW

sobieslaw.kozlowski@noblesecurities.pl tel: +48 22 213 22 39 model portfolios

Krzysztof Radojewski

krzysztof.radojewski@noblesecurities.pl tel: +48 22 213 22 35 biotechnology

Michał Sztabler

michal.sztabler@noblesecurities.pl tel: +48 22 213 22 36 industrials. utillities. mining

Dariusz Dadej

dariusz.dadej@noblesecurities.pl tel: +48 22 660 24 83 retail. industrials

Krzysztof Ojczyk. MPW

krzysztof.ojczyk@noblesecurities.pl tel: +48 12 422 31 00 Technical analysis

Mateusz Chrzanowski

mateusz.chrzanowski@noblesecurities.pl tel.: +48 785 904 686 industrials. automotive. gaming

Dariusz Nawrot

dariusz.nawrot@noblesecurities.pl tel. +48 783 931 515 construction. real estate. industry.

Jacek Borawski

jacek.borawski@noblesecurities.pl Technical analysis

